Levofloxacin Kabi (Levofloxacin Hemihydrate)

Levofloxacin works by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition stops bacterial cell division and leads to bacterial cell death.

The dosage and duration of Levofloxacin Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local guidelines. No fixed regimen is provided here.

Levofloxacin is classified as a pregnancy category with limited data. It should only be used during pregnancy or lactation when the potential benefits justify the potential risks, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Levofloxacin offers broad‑spectrum activity against Gram‑negative and Gram‑positive bacteria and has a convenient once‑daily dosing schedule when given intravenously. Compared with older fluoroquinolones, it often provides improved potency against respiratory pathogens and a lower risk of certain resistance mechanisms.

Levofloxacin Kabi should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability.

Levofloxacin Kabi is administered by intravenous infusion. The infusion rate and dilution volume are determined by the healthcare professional according to the patient’s clinical condition and institutional protocols.

Serious risks include tendon rupture or tendinitis, QT‑interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and central nervous system effects like seizures, especially in patients with pre‑existing CNS disorders.

Patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with prolonged QT interval not corrected, and patients taking medications that strongly interact (e.g., certain antacids, warfarin, theophylline) should avoid using Levofloxacin Kabi unless specifically directed by a physician.